Complete remission · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in treatment response at 52 weeks: complete remission (primary outcome… compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
1 finding from 1 review
Partial remission ( · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in treatment response at 52 weeks: partial remission (primary outcome 3) compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
1 finding from 1 review
Sustainable remission between 52 and 78 weeks: complete or partial remission (primary outcome 1, 2, 3) · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in sustainable remission between 52 and 78 weeks: complete or partial… compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
1 finding from 1 review
CKD or death: death by 52 weeks · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in CKD or death: death by 52 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
CKD or death: 50% decline in GFR by 78 weeks · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in CKD or death: 50% decline in GFR by 78 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Adverse effects (weeks 0 to 26): serious infection requiring hospitalisation · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): serious infection requiring… compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Adverse events: hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): hypertension compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Complete or partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus may leads to higher number with complete or partial response at one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
Complete response · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus may leads to higher number with complete response at one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
Primary outcome: partial clinical response · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus showed no clear difference in number with partial response at one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
Number with treatment failure by one year · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus may leads to lower number with treatment failure by one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
Frequent relapses · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus may leads to lower number with frequent relapses by one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
Number with steroid resistance by one year · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus showed no clear difference in number with steroid resistance by one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
Change in GFR · idiopathic steroid‐resistant nephrotic syndrome in children
1 finding from 1 review
Death · Patients with maintenance treatment in lupus nephritis
It is very uncertain whether azathioprine (AZA) changes death compared with mycophenolate mofetil (MMF) (very low certainty).
1 finding from 1 review
ESKD · Patients with maintenance treatment in lupus nephritis
It is very uncertain whether azathioprine (AZA) changes ESKD compared with mycophenolate mofetil (MMF) (very low certainty).
1 finding from 1 review
Renal relapse · Patients with maintenance treatment in lupus nephritis
Azathioprine (AZA) probably leads to higher renal relapse compared with mycophenolate mofetil (MMF) (moderate certainty).
1 finding from 1 review
Doubling serum creatinine · Patients with maintenance treatment in lupus nephritis
Azathioprine (AZA) may leads to higher doubling of serum creatinine compared with mycophenolate mofetil (MMF) (low certainty).
1 finding from 1 review
Major infection · Patients with maintenance treatment in lupus nephritis
Azathioprine (AZA) showed no clear difference in major infection compared with mycophenolate mofetil (MMF) (low certainty).
1 finding from 1 review
Leucopenia · Patients with maintenance treatment in lupus nephritis
Azathioprine (AZA) may leads to higher leucopenia compared with mycophenolate mofetil (MMF) (low certainty).
1 finding from 1 review